Serious unpredictable reactions occurring in real-world use of the interleukin-6 receptor antagonist tocilizumab have been reported by researchers at the University of Bologna, Italy. Increased off-label use of tocilizumab in patients with severe COVID-19 infections has prompted the characterisation of clinically relevant adverse events associated with the drug as an aid to patient management.

The group conducted a disproportionality analysis using the US FDA Adverse Events Reporting System (FAERS) database, selecting designated medical events (DMEs) as a means of assigning clinical priority to emerging safety issues, with particular focus on hepatic reactions where tocilizumab was identified as a suspected cause.

Reporting odds ratio (ROR) was calculated as a measure of disproportionality by comparing DMEs reported in cases and studies of tocilizumab with all other drugs and events recorded in FAERS.

DMEs that demonstrated significant disproportionality were classified into three groups: expected (based on previous pivotal trials), disease-related, and unpredictable (pharmacodynamically-based).

Of the 44 DMEs assessed, 13 demonstrated ROR disproportionality. Of these, drug-induced liver injury (DILI) (n=91; ROR 3.77; 95% CI 3.07−4.64), pancreatitis (151; 1.65; 1.41−1.94), and acute pancreatitis (61; 1.99; 1.55−2.56) were unpredictable events, and six and four DMEs were disease-related and expected DMEs, respectively.

Disproportionality analysis was performed for five liver-related DMEs but only the ROR for DILI was statistically significant. The median onset for all liver-related DMEs was 27.5 days (range: 15 days for DILI to 94 days for hepatic fulminant). The death rate for all liver-related DMEs was 18.4% (range: 0 for hepatitis autoimmune to 60% for hepatitis fulminant).

Given the increasing, off-label use of tocilizumab in the clinical management of severe COVID-19 infection, the identification of a number of unpredictable DMEs, namely DILI and acute pancreatitis may help in the monitoring of these patients where there is potential for the emergence of life-threatening, unpredictable adverse events to occur.
